Uchiyama, N; Matsuda, S; Kawamura, M; Kikura-Hanajiri, R; Goda, Y. Identification of two new-type designer drugs, piperazine derivative MT-45 (I-C6) and synthetic peptide Noopept (GVS-111), with synthetic cannabinoid A-834735, cathinone derivative 4-methoxy-α-PVP, and phenethylamine derivative 4-methylbuphedrine from illegal products. Forensic Toxicol., 1 Jan 2014, 32 (1), 9–18. 678 kB. https://doi.org/10.1007/s11419-013-0194-5
McLaughlin, G; Morris, N; Kavanagh, PV; Power, JD; O’Brien, J; Talbot, B; Elliott, SP; Wallach, J; Hoang, K; Morris, H; Brandt, SD. Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta- and para-substituted isomers. Drug Test. Analysis, 1 Jan 2016, 8 (1), 98-109. 1.2 MB. https://doi.org/10.1002/dta.1800 #MT-45 GC,LC,MS,NMR,TLC
Wallach, J; Kavanagh, PV; McLaughlin, G; Morris, N; Power, JD; Elliott, SP; Mercier, MS; Lodge, D; Morris, H; Dempster, NM; Brandt, SD. Preparation and characterization of the ‘research chemical’ diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers. Drug Test. Analysis, 1 May 2015, 7 (5), 358-367. 632 kB. https://doi.org/10.1002/dta.1689
Elliott, SP; Brandt, SD; Smith, C. The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis. Drug Test. Analysis, 1 Aug 2016, 8 (8), 875-879. 791 kB. https://doi.org/10.1002/dta.1984
Fabregat-Safont, D; Carbón, X; Ventura, M; Fornís, I; Guillamón, E; Sancho, JV; Hernández, F; Ibáñez, M. Updating the list of known opioids through identification and characterization of the new opioid derivative 3,4-dichloro-N-(2-(diethylamino)cyclohexyl)-N-methylbenzamide (U-49900). Sci. Rep., 24 Jul 2017, 7 (1), 6338. 3.1 MB. https://doi.org/10.1038/s41598-017-06778-9
EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2015. 879 kB.
EMCDDA. New drugs in Europe, 2013, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2014. 311 kB.
Zawilska, JB; Andrzejczak, D. Next generation of novel psychoactive substances on the horizon – A complex problem to face. Drug Alcohol Depend., 1 Jan 2015, 157, 1-17. 3.0 MB. https://doi.org/10.1016/j.drugalcdep.2015.09.030
Sommerfeld-Klatta, K; Artur Teżyk; Geppert, B. Toxicological analysis of new opioids. In Chromatographic Techniques in the Forensic Analysis of Designer Drugs; Kowalska, T; Sajewicz, M; Sherma, J, Eds., CRC Press, Taylor & Francis Group, 1 Jan 2018; pp 391–417. 746 kB.
Wallach, J; Brandt, SD. 1,2-Diarylethylamine- and ketamine-based new psychoactive substances. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 305-352. 593 kB. https://doi.org/10.1007/164_2018_148 #MT-45
EMCDDA. Report on the risk assessment of MT-45, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Oct 2015. 814 kB. #MT-45 MS,IR,UV
Beardsley, PM; Zhang, Y. Synthetic opioids. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 353–381. 464 kB. https://doi.org/10.1007/164_2018_149 #MT-45
Kronstrand, R; Guerrieri, D; Vikingsson, S; Wohlfarth, A; Gréen, H. Fatal poisonings associated with new psychoactive substances. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 495–541. 477 kB. https://doi.org/10.1007/164_2018_110 #MT-45
Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 1 May 2019, 298 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #MT-45
Armenian, P; Vo, KT; Barr-Walker, J; Lynch, KL. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology, 1 May 2018, 134 121–132. 847 kB. https://doi.org/10.1016/j.neuropharm.2017.10.016 #MT-45